Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 20/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.51 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708852 | 0.94 | DPP4 (0.54) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL14558290 | 0.92 | DPP4 (0.57) | DPP4DPP8DPP7DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL5651865 | 0.78 | DPP4 (0.63) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL14558291 | 0.77 | KDM4E (0.43) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL1070721 | 0.77 | PREP (0.39) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL14558293 | 0.75 | KDM4E (0.51) | DPP4DPP8DPP7DPP9 | |
| Trifluoroacetic Acid SCHEMBL6824122 | 0.75 | DPP4 (0.84) | DPP4DPP8DPP7DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL5871430 | 0.75 | DPP4 (0.61) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL14558295 | 0.75 | DPP4 (0.56) | DPP4DPP8DPP7DPP9FAP | |
| Trifluoroacetic Acid SCHEMBL6820670 | 0.72 | DPP4 (0.84) | DPP4DPP8DPP7DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209891-A1 | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2004-10-21 | — | — | US | disclosed |
| EP-1377278-A1 | TREATMENT OF TYPE 2 DIABETES WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Ferring BV (NL) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083109-A1 | TREATMENT OF TYPE 2 DIABETES WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING BV (NL) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209891-A1 | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.